Back to Search
Start Over
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
- Source :
- Breast Cancer Research; 1/31/2020, Vol. 22 Issue 1, p1-3, 3p
- Publication Year :
- 2020
-
Abstract
- <bold>Background: </bold>There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).<bold>Methods: </bold>Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) in breast cancer.<bold>Results: </bold>We describe results from clinical studies reporting the effect of anti-HER2 strategies particularly ADCs and their mechanistic effect. We review biological findings underlying HER2 heterogeneity and its implication in the development of novel anti-HER2 drugs including new ADCs in clinical development like trastuzumab deruxtecan (DS-8201).<bold>Conclusions: </bold>We suggest potential mechanisms to optimize these compounds and their future clinical implementation. [ABSTRACT FROM AUTHOR]
- Subjects :
- ANTIBODY-drug conjugates
HETEROGENEITY
BREAST cancer
Subjects
Details
- Language :
- English
- ISSN :
- 14655411
- Volume :
- 22
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Breast Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- 141512305
- Full Text :
- https://doi.org/10.1186/s13058-020-1252-7